[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1103730A1 - Pyrrolopyridine derivatives and their use as crth2antagonists - Google Patents

Pyrrolopyridine derivatives and their use as crth2antagonists

Info

Publication number
HK1103730A1
HK1103730A1 HK07108031A HK07108031A HK1103730A1 HK 1103730 A1 HK1103730 A1 HK 1103730A1 HK 07108031 A HK07108031 A HK 07108031A HK 07108031 A HK07108031 A HK 07108031A HK 1103730 A1 HK1103730 A1 HK 1103730A1
Authority
HK
Hong Kong
Prior art keywords
pyrrolopyridine derivatives
pyrrolopyridine
derivatives
Prior art date
Application number
HK07108031A
Other languages
English (en)
Inventor
Bala Kamlesh
Leblanc Catherine
Sandham David Andrew
Turner Katharine
Watson Simon James
Brown Lyndon Nigel
Cox Brian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0413619A external-priority patent/GB0413619D0/en
Priority claimed from GB0507693A external-priority patent/GB0507693D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1103730A1 publication Critical patent/HK1103730A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK07108031A 2004-06-17 2007-07-24 Pyrrolopyridine derivatives and their use as crth2antagonists HK1103730A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0413619A GB0413619D0 (en) 2004-06-17 2004-06-17 Organic compounds
GB0507693A GB0507693D0 (en) 2005-04-15 2005-04-15 Organic compounds
PCT/EP2005/006493 WO2005123731A2 (en) 2004-06-17 2005-06-16 Pyrrolopyridine derivatives and their use as crth2 antagonists

Publications (1)

Publication Number Publication Date
HK1103730A1 true HK1103730A1 (en) 2007-12-28

Family

ID=35510318

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07108031A HK1103730A1 (en) 2004-06-17 2007-07-24 Pyrrolopyridine derivatives and their use as crth2antagonists

Country Status (29)

Country Link
US (5) US7666878B2 (da)
EP (1) EP1761529B3 (da)
JP (1) JP4886680B2 (da)
KR (1) KR101183330B1 (da)
AR (1) AR049443A1 (da)
AT (1) ATE378338T1 (da)
AU (1) AU2005254681B2 (da)
BR (1) BRPI0512060B8 (da)
CA (1) CA2569125C (da)
CY (1) CY1107851T1 (da)
DE (1) DE602005003365T3 (da)
DK (1) DK1761529T3 (da)
EC (1) ECSP067077A (da)
ES (1) ES2294717T7 (da)
HK (1) HK1103730A1 (da)
HR (1) HRP20080022T4 (da)
IL (1) IL179604A (da)
MA (1) MA28666B1 (da)
MX (1) MXPA06014694A (da)
MY (1) MY144903A (da)
NO (1) NO338319B1 (da)
NZ (1) NZ551439A (da)
PE (1) PE20060301A1 (da)
PL (1) PL1761529T6 (da)
PT (1) PT1761529E (da)
RS (1) RS50552B (da)
RU (1) RU2379309C2 (da)
TW (1) TWI352702B (da)
WO (1) WO2005123731A2 (da)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525144D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) * 2005-12-13 2006-01-18 Novartis Ag Organic compounds
KR101426093B1 (ko) 2006-02-10 2014-08-01 서미트 코포레이션 피엘씨 뒤시엔느 근이영양증의 치료
GB0611695D0 (en) * 2006-06-13 2006-07-26 Novartis Ag Organic compounds
SI2051962T1 (sl) 2006-08-07 2012-02-29 Actelion Pharmaceuticals Ltd Derivati (3-amino-1,2,3,4-tetrahidro-9h-karbazol-9-il)-ocetne kisline
RS55735B1 (sr) * 2007-08-03 2017-07-31 Summit (Oxford) Ltd Kombinacije lekova za lečenje dišenove mišićne distrofije
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
US8101645B2 (en) 2008-02-15 2012-01-24 Abbott Laboratories Thienopyrroles and pyrrolothiazoles as new therapeutic agents
EP2315590B1 (en) 2008-08-15 2012-09-26 N30 Pharmaceuticals, LLC Pyrrole inhibitors of s-nitrosoglutathione reductase
JP5688366B2 (ja) * 2008-08-15 2015-03-25 エヌサーティー・ファーマシューティカルズ・インコーポレーテッド 治療薬剤としての、ｓ−ニトロソグルタチオンレダクターゼの新規ピロール阻害剤
US8673961B2 (en) 2008-08-15 2014-03-18 N30 Pharmaceuticals, Inc. Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents
CN102791689B (zh) 2010-03-22 2014-10-29 埃科特莱茵药品有限公司 3-（杂芳基-氨基）-1,2,3,4-四氢-9h-咔唑衍生物及其作为前列腺素d2受体调节剂的用途
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
KR20130133219A (ko) * 2010-12-23 2013-12-06 머크 샤프 앤드 돔 코포레이션 Crth₂ 수용체 조절제로서의 퀴녹살린 및 아자-퀴녹살린
EP2661265B1 (en) 2010-12-23 2017-03-08 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as crth2 receptor modulators
SG193902A1 (en) 2011-04-14 2013-11-29 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
BR112014009108A2 (pt) 2011-10-25 2017-04-18 Shionogi & Co derivado heterocíclico tendo atividade antagonista de receptor de pgd2
EP2790696A1 (en) 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
MY179356A (en) 2014-03-17 2020-11-05 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2015140701A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
HRP20220522T1 (hr) 2014-08-04 2022-06-10 Nuevolution A/S Proizvoljno kondenzirani heterociklil-supstituirani derivati pirimidina koji su korisni za liječenje upalnih, metaboličkih, onkoloških i autoimunih bolesti
JP6770522B2 (ja) 2015-02-13 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
BR112018001267A2 (pt) 2015-07-23 2019-10-22 Merck Sharp & Dohme método de diagnosticar asma, uso de um antagonista do receptor de crth2, produto de fármaco, e, kit
CA2993893A1 (en) 2015-09-15 2017-03-23 Idorsia Pharmaceuticals Ltd Crystalline forms
EP4119539A1 (en) 2015-09-23 2023-01-18 XWPharma Ltd. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
CA2998278A1 (en) * 2015-09-29 2017-04-06 Novartis Ag Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1h-pyrrolo [2,3-b]pyridin-3-yl-acetic acid
WO2017210261A1 (en) * 2016-05-31 2017-12-07 Concert Pharmaceuticals, Inc. Deuterated fevipiprant
SG11201810600WA (en) 2016-06-13 2018-12-28 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CN106188040B (zh) * 2016-06-28 2018-03-23 浙江宏鑫染化材料有限公司 一种Fevipiprant及其中间体的制备方法
CN109563093B (zh) 2016-07-21 2021-09-03 正大天晴药业集团股份有限公司 作为crth2抑制剂的三并环类化合物
PL4122464T3 (pl) 2017-03-28 2024-09-16 Gilead Sciences, Inc. Kombinacje terapeutyczne do leczenia chorób wątroby
EP3601235A4 (en) 2017-03-30 2020-11-18 XW Laboratories Inc. BICYCLIC HETERARYL DERIVATIVES, PREPARATION AND ASSOCIATED USES
JOP20190223A1 (ar) 2017-04-01 2019-09-26 Novartis Ag عملية لتحضير حمض 1-(4- ميثان سلفونيل -2- تراي فلورو ميثيل - بنزيل)-2- ميثيل -1h- بيرولو [2، 3-b] بيريدين -3- يل- أسيتيك
CN110944634A (zh) 2017-06-30 2020-03-31 加利福尼亚大学董事会 用于调节毛发生长的组合物和方法
WO2019011336A1 (zh) * 2017-07-14 2019-01-17 苏州科睿思制药有限公司 Qaw-039的晶型及其制备方法和用途
WO2019130166A1 (en) * 2017-12-26 2019-07-04 Mankind Pharma Ltd. Preparation of 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoro methyl)phenyl]methyl] pyrrolo[2,3-b]pyridin-3-yl]acetic acid
EP3741754A4 (en) 2018-01-19 2021-06-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. INDOLE DERIVATIVE CRYSTALLINE FORM AND PROCESS OF PREPARATION AND USE
CN110467612B (zh) * 2018-05-09 2020-09-25 新发药业有限公司 一种前列腺素d2受体抑制剂化合物的简便制备方法
CN114042070A (zh) 2018-09-30 2022-02-15 凯瑞康宁生物工程（武汉）有限公司 作为神经元组胺受体-3拮抗剂的化合物及其用途
HUE065889T2 (hu) 2019-01-15 2024-06-28 Gilead Sciences Inc Izoxazol vegyület mint FXR agonista és az azt tartalmazó gyógyszerészeti készítmények
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
TW202136194A (zh) 2019-12-20 2021-10-01 香港商凱瑞康寧有限公司 ４－纈胺醯氧基丁酸的合成方法
CA3160522A1 (en) 2019-12-20 2021-06-24 Sanne Schroder Glad Compounds active towards nuclear receptors
AU2021249530A1 (en) 2020-03-31 2022-12-01 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
AU2021292406B2 (en) 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
KR20230008190A (ko) 2020-06-18 2023-01-13 엑스더블유파마 리미티드 수용성 원료의약품의 약학적 과립화제
US11896573B2 (en) 2020-07-24 2024-02-13 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
WO2022076466A1 (en) 2020-10-05 2022-04-14 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
EP4308086A1 (en) 2021-03-19 2024-01-24 XWPharma Ltd. Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320268A (en) * 1964-08-14 1967-05-16 Merck & Co Inc 1-aroyl or heteroaroyl-7-azaindole-3-carboxylates and derivatives
US5212195A (en) * 1992-05-13 1993-05-18 Syntex (U.S.A.) Inc. Substituted indole antagonists derivatives which are angiotensin II
GB9319297D0 (en) 1993-09-17 1993-11-03 Wellcome Found Indole derivatives
JPH10510510A (ja) 1994-06-09 1998-10-13 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗物質
CN1056611C (zh) * 1994-06-16 2000-09-20 美国辉瑞有限公司 吡唑并吡啶和吡咯并吡啶,其用途和用于制备它们的中间体
TWI262920B (en) 2000-10-27 2006-10-01 Elbion Ag New 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them
EP1424325A4 (en) * 2001-09-07 2005-12-21 Ono Pharmaceutical Co INDOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE AGENT
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
US7534897B2 (en) * 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
SE0201635D0 (sv) * 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
WO2005040112A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525144D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) * 2005-12-13 2006-01-18 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20140309254A1 (en) 2014-10-16
DE602005003365T3 (de) 2012-08-30
CA2569125C (en) 2013-01-08
PL1761529T6 (pl) 2011-11-30
PL1761529T3 (pl) 2008-04-30
US8455645B2 (en) 2013-06-04
MY144903A (en) 2011-11-30
IL179604A (en) 2014-04-30
MA28666B1 (fr) 2007-06-01
PE20060301A1 (es) 2006-05-18
RS50552B (sr) 2010-05-07
MXPA06014694A (es) 2007-02-12
US20100204225A1 (en) 2010-08-12
NO338319B1 (no) 2016-08-08
KR101183330B1 (ko) 2012-09-17
PT1761529E (pt) 2008-02-11
TWI352702B (en) 2011-11-21
US9169251B2 (en) 2015-10-27
EP1761529A2 (en) 2007-03-14
EP1761529B1 (en) 2007-11-14
CY1107851T1 (el) 2013-06-19
US20100210610A1 (en) 2010-08-19
CA2569125A1 (en) 2005-12-29
DE602005003365D1 (de) 2011-01-05
RU2007101277A (ru) 2008-07-27
WO2005123731A3 (en) 2006-05-04
US20080114022A1 (en) 2008-05-15
IL179604A0 (en) 2007-05-15
BRPI0512060B8 (pt) 2021-05-25
JP4886680B2 (ja) 2012-02-29
US7666878B2 (en) 2010-02-23
AU2005254681B2 (en) 2009-01-29
AU2005254681A1 (en) 2005-12-29
BRPI0512060B1 (pt) 2018-08-07
ATE378338T1 (de) 2007-11-15
DE602005003365T2 (de) 2008-09-11
NO20070323L (no) 2007-03-12
US20130267518A1 (en) 2013-10-10
AR049443A1 (es) 2006-08-02
US8791256B2 (en) 2014-07-29
NZ551439A (en) 2009-09-25
TW200617009A (en) 2006-06-01
EP1761529B3 (en) 2011-06-15
ES2294717T3 (es) 2008-04-01
US8470848B2 (en) 2013-06-25
RU2379309C2 (ru) 2010-01-20
JP2008502638A (ja) 2008-01-31
ES2294717T7 (es) 2012-06-14
ECSP067077A (es) 2007-01-26
BRPI0512060A (pt) 2008-02-06
WO2005123731A2 (en) 2005-12-29
HRP20080022T4 (hr) 2011-10-31
HRP20080022T3 (en) 2008-02-29
DK1761529T3 (da) 2008-03-25
KR20070032694A (ko) 2007-03-22

Similar Documents

Publication Publication Date Title
HK1103730A1 (en) Pyrrolopyridine derivatives and their use as crth2antagonists
HK1104175A1 (en) Pyrrolopyridine derivatives
IL196021A0 (en) Pyrazolopyridine derivatives uses
HK1101911A1 (en) Tetrahydrocarbozoles and derivatives
ZA200606678B (en) 2-Pyridinylethylcarboxamide derivatives and their use as fungicides
EP1951680A4 (en) NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE
IL180682A0 (en) N-hydroxamide derivatives, their preparation and use
IL178765A0 (en) 2-pyridinylcycloalkylbenzamide derivatives and their use as fungicides
IL178888A0 (en) Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives
IL184008A0 (en) 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments
PL2215908T3 (pl) 2-alkilo-cykloalk(en)ylo-karboksamidy i ich zastosowanie jako fungicydów
ZA200704650B (en) 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments
ZA200609864B (en) Pyrrolopyridine derivatives
EP1810976A4 (en) BENZONAPHTHACENEGLYCOSIDE DERIVATIVE AND THE USE THEREOF
IL183705A (en) Macrocyclic quinazole derivatives and their use as mtki
ZA200705046B (en) Macrocyclic quinazole derivatives and their use as MTKI
GB0427723D0 (en) Compounds and their use
SI1761529T1 (sl) Derivati pirolopiridina in njihova uporaba kot antagonisti CRTh2
GB0405304D0 (en) Compounds and their use
GB0403953D0 (en) Compounds and their use
GB0401244D0 (en) Compounds and their use
GB0402903D0 (en) Compounds and their use
GB0423234D0 (en) Compounds and their use
GB0416630D0 (en) Compounds and their use
GB0402905D0 (en) Compounds and their use

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230616